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In addition to treating depression, antidepressant drugs are also a first-line treatment for neuropathic pain, which is pain secondary to
lesion or pathology of the nervous system. Despite thewidespread use of these drugs, themechanismunderlying their therapeutic action
in this pain context remains partly elusive. The present study combined data collected in male and female mice from a model of
neuropathic pain and data from the clinical setting to understand how antidepressant drugs act. We show two distinct mechanisms by
which the selective inhibitor of serotonin and noradrenaline reuptake duloxetine and the tricyclic antidepressant amitriptyline relieve
neuropathic allodynia. One of these mechanisms is acute, central, and requires descending noradrenergic inhibitory controls and 2A
adrenoceptors, as well as the mu and delta opioid receptors. The second mechanism is delayed, peripheral, and requires noradrenaline
from peripheral sympathetic endings and 2 adrenoceptors, as well as the delta opioid receptors. We then conducted a transcriptomic
analysis in dorsal root ganglia, which suggested that the peripheral component of duloxetine action involves the inhibition of neuroim-
mune mechanisms accompanying nerve injury, including the downregulation of the TNF-–NF-B signaling pathway. Accordingly,
immunotherapies against either TNF- or Toll-like receptor 2 (TLR2) provided allodynia relief. We also compared duloxetine plasma
levels in the animal model and in patients and we observed that patients’ drug concentrations were compatible with those measured in
animals under chronic treatment involving the peripheral mechanism. Our study highlights a peripheral neuroimmune component of
antidepressant drugs that is relevant to their delayed therapeutic action against neuropathic pain.
Key words: amitriptyline; antidepressants; duloxetine; neuropathic pain; TLR2; TNF-
Introduction
Understanding the mechanisms underlying currently used phar-
macological treatments of a disease can be critical to provide
insights into the pathology itself and hints toward new treat-
ments. In the early 1960s, it was fortuitously observed that a
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Significance Statement
In addition to treating depression, antidepressant drugs are also a first-line treatment for neuropathic pain, which is pain second-
ary to lesion or pathology of the nervous system.However, themechanismbywhich antidepressant drugs can relieve neuropathic
pain remained in part elusive. Indeed, preclinical studies led to contradictions concerning the anatomical and molecular sub-
strates of this action. In the present work, we overcame these apparent contradictions by highlighting the existence of two
independent mechanisms. One is rapid and centrally mediated by descending controls from the brain to the spinal cord and the
other is delayed, peripheral, and relies on the anti-neuroimmune action of chronic antidepressant treatment.
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tricylic antidepressant used in the psychiatry field might also re-
lieve neuropathic pain (Paoli et al., 1960), which is pain consec-
utive to a lesion or pathology of the somatosensory system
(Treede et al., 2008). In the 1970s and 1980s, this observation was
confirmed by controlled studies (Watson et al., 1982; Max et al.,
1987) and tricylic antidepressants were recognized as first-line
treatments against neuropathic pain (Finnerup et al., 2015), this
action being clinically disconnected from their impact on depres-
sion (Mico´ et al., 2006; Perahia et al., 2006). Early in this century,
antidepressants that are more selective inhibitors of serotonin
and noradrenaline reuptake (SSNRIs), such as duloxetine, were
approved by various agencies as treatment for painful diabetic
peripheral neuropathy (Kremer et al., 2016a). Today, these drugs
are frequently used to treat a wide variety of neuropathic pain.
However, detailed mechanism by which antidepressant drugs re-
lieve painful symptoms remains elusive, with apparent contra-
dictions in the scientific literature (Kremer et al., 2016a). It is
often acknowledged that antidepressants would act through de-
scending aminergic pathways from the locus coeruleus to the
spinal cord and inhibit nociceptive processing (Ardid and Guil-
baud, 1992; Suzuki et al., 2008; Arsenault and Sawynok, 2009).
However, a peripheral mechanism has also been proposed to
explain the action of the tricyclic antidepressant nortriptyline
(Bohren et al., 2013). Whereas a main contribution of 2 adre-
noceptors is usually considered as critical (Ozdog˘an et al., 2004;
Cegielska-Perun et al., 2013; Hajhashemi et al., 2014), a loss of
anti-allodynic action has been observed for certain antidepres-
sant drugs in mice deficient for 2 adrenoceptors (Yalcin et al.,
2009a,b; Bohren et al., 2013; Choucair-Jaafar et al., 2014). In
addition, despite general consensus about involvement of opioid
receptors, discrepancies remain as to receptor type and anatom-
ical localization (Schreiber et al., 1999; Marchand et al., 2003;
Benbouzid et al., 2008b; Bohren et al., 2010; Choucair-Jaafar et
al., 2014; Megat et al., 2015).
Here, we investigated the anti-allodynic action of the SSNRI du-
loxetine in two different paradigms in a mouse model of neuropathic
pain. We also compared plasma concentrations in these procedures
to those observed in the clinical setting. We show that duloxetine and
the tricylic antidepressant amitriptyline exert acute anti-allodynic
action through central 2A adrenoceptor-dependent mechanism
and chronic pain relief through a peripheral and 2 adrenoceptors
dependent mechanism that relies on an anti-neuroimmune action
of the drug. We further substantiate our findings by bringing evi-
dence that the peripheral mechanism is compatible with plasma lev-
els of duloxetine in patients.
Materials andMethods
Study
The purpose of this study was to understand how duloxetine relieves
neuropathic pain. Using a mouse model, a mechanistic dissection was
performed and compared with the action of a tricyclic antidepressant,
amitriptyline. Results highlighted that two independent mechanisms can
mediate the action of duloxetine. A co-clinical study was then conducted
to compare the plasma levels of duloxetine in neuropathic pain patients
and in an animal model. Because the results highlighted the possible
relevance of the chronic mechanism of duloxetine, we further explored
this mechanism by a transcriptomic analysis. A schematic of the time
course of experimental procedures is presented in Figure 1.
Animals
All animal studies were performed in agreement with European guidelines
(EU 2010/63) and under protocols approved by the Comite´ d’Ethique en
Matie`re d’Expe´rimentation Animale de Strasbourg (CREMEAS, CEEA35).
Experiments were performed using C57BL/6J mice (Charles River Labora-
tories), 8–10 weeks old at surgery time, or with male and female mice lacking
2 adrenoceptors,-opioid receptors (MOR),-opioid receptors (DOR), or
-opioid receptors (KOR) and their littermate controls. The generation of
mice lacking MOR, DOR, or KOR, created in the laboratory of Brigitte
Kieffer (IGBMC, Strasbourg, France), has been described previously (Mat-
thes et al., 1996; Simonin et al., 1998; Filliol et al., 2000). Mice lacking 2
adrenoceptors were created in the laboratory of Brian Kobilka (Stanford
University, Stanford, CA) and have been described previously (Chruscinski
et al., 1999). Heterozygote mice were bred in our animal facilities, genotyp-
ing of the litters was done, and the experiments were conducted on adult
male and female WT and KO littermate mice weighing 20–30 g. The same
number of males and females was used in each experimental group. Because
the WT animals have the same background and the same behavioral pheno-
type, they were pooled to form the control groups. Mice were group-housed
two to five per cage and kept under a 12 h light/dark cycle with food and
water ad libitum. In pharmacological studies, mice were randomly assigned
to experimental groups. The experimenter was always blinded to both geno-
type and treatment.
Neuropathic pain model
Neuropathic pain was induced by cuffing the main branch of the right
sciatic nerve (Benbouzid et al., 2008a; Yalcin et al., 2014). Surgeries were
performed under ketamine (68 mg/kg)/xylazine (10 mg/kg) intraperito-
neal anesthesia (Centravet). The common branch of the right sciatic
nerve was exposed and a cuff of PE-20 polyethylene tubing (Harvard
Apparatus) of standardized length (2 mm) was unilaterally inserted
around it (Cuff group). The shaved skin was closed using suture. Sham-
operated mice underwent the same surgical procedure without implan-
tation of the cuff (Sham group).
Measure of mechanical allodynia
Mechanical allodynia (a symptom of neuropathic pain) was tested using
von Frey hairs and results were expressed in grams (Barrot, 2012). Tests
were performed during the morning starting at least 2 h after lights on.
Mice were placed in clear Plexiglas boxes (7 cm  9 cm  7 cm) on an
elevated mesh floor. Calibrated von Frey filaments (Bioseb) were applied
to the plantar surface of each hindpaw until they just bent in a series of
ascending forces up to the mechanical threshold. Filaments were tested
five times per paw and the paw withdrawal threshold (PWT) was defined
as the lower of two consecutive filaments for which three or more with-
drawals out of the five trials were observed (Benbouzid et al., 2008a;
Bohren et al., 2010; Yalcin et al., 2014).
Treatment procedures
Long-term and acute drug treatment experiments were conducted on
independent sets of mice. The long-term treatment with antidepressants
began at least 2 weeks after the surgical procedure (cuff implantation or
sham surgery). Duloxetine (Interchim, D4223) and amitriptyline
(Sigma-Aldrich) were delivered p.o. (200, 150, 100, or 50g/ml) through
the drinking water with ad libitum access as sole source of fluid. The
drugs were dissolved in water with 0.2% saccharin to increase palatability
and control mice were given a solution of 0.2% saccharin in water (vehi-
cle solution). To assess the daily dose of antidepressant that was actually
received by the animals (in mg/kg/d), the bottles containing the treat-
ment were weighed daily and we calculated the ratio between the intake
amount of antidepressant per cage and the weight of the animals. For
acute administration, duloxetine or amitriptyline was usually dissolved
in water with 0.2% saccharin and administered p.o. (15, 20, or 30 mg/kg,
10 ml/kg) with feeding needles (Cadence Science, 7921) except for nor-
adrenergic lesion experiments, for which amitriptyline was administered
intraperitoneally (15 mg/kg, 5 ml/kg), dissolved in 0.9% NaCl. Yohim-
bine (20 g/ml; Sigma-Aldrich), an antagonist of 2 adrenoceptors, and
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Figure 1. Time course of experiments. For all experiments, the baseline mechanical threshold was assessed with von Frey filaments before the surgical procedure (cuff implantation or sham
surgery). The treatments began at least 2 weeks after this surgical procedure. A, Experimental design for dose–response experiments, studies in transgenic mice, and morphological or molecular
analyses (mass spectrometry, RNA sequencing, Western blot). B, Experimental design for lesion experiments. C, Experimental design for siRNAs’ effect on acute antidepressant action. D, Experi-
mental design for antagonists’ effect on acute antidepressant action. NLX, Naloxone; NLX Meth, naloxone methiodide; MNTX, methylnaltrexone. E, Experimental design for antagonists’ effect on
chronic antidepressant action. Dul, Duloxetine; Ami, amitriptyline.
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propranolol (50 g/ml; Sigma-Aldrich), a nonselective antagonist of 
adrenoceptors, were delivered p.o. through the drinking water. Mice
received these antagonists for 5 d starting 2 weeks after the beginning of
the long-term treatment in cotreatment with duloxetine or vehicle for
chronic experiments or for 5 d before acute administration of duloxetine
for acute experiments. The injection of naloxone methiodide (NLX
Meth, 5 mg/kg, s.c.; Sigma-Aldrich), a nonselective antagonist of opioid
receptors which does not cross the blood– brain barrier, was performed
after 25 d of duloxetine or amitriptyline treatment or 90 min after the
acute administration of duloxetine. The injection of naloxone, a non-
selective antagonist of opioid receptors (NLX, 1 mg/kg, s.c.; Sigma-
Aldrich), and of methylnaltrexone, a nonselective antagonist of opioid
receptors that cannot cross the blood– brain barrier (MNTX, 10 mg/kg,
s.c.; Sigma-Aldrich), were done 90 min after the acute administration of
duloxetine. To inhibit the NF-B pathway, mice received two injections
per day (morning and evening) of pyrrolidine dithiocarbamate (PDTC,
20 mg/kg, 5 ml/kg, i.p.; Sigma-Aldrich) dissolved in 0.9% NaCl solution
that was also used for control injections. Treatment with the anti-TNF-
drugs adalimumab (Humira, AbbVie, 1 mg/kg) or certolizumab pegol
(Cimzia, UCB, 6 mg/kg) began 15 days after the nerve injury and was
maintained for 17 days. During anti-TNF- treatment, the mice received
1 injection every 4 d then every 2 d (morning). Drugs were dissolved in
0.9% NaCl solution that was also used for control injections and they
were administered subcutaneously in a volume of 5 ml/kg. For in vivo
anti-Toll-like receptor 2 (TLR2) experiments, mice were treated with
TLR2 and TLR4 antagonist RS-LPS (0.1 mg/kg, 5 ml/kg in 0.9% NaCl,
i.p.; InvivoGen) twice a day for 1 week or with neutralizing anti-TLR2
antibody (T2.5, 2 g per mouse, i.v. retroorbitally; InvivoGen) every 4 d
and then every 2 d for 15 days. For cellular and molecular experiments,
dorsal root ganglia and/or blood were collected at selected time after
acute administration or after 3 weeks of chronic treatment.
Noradrenergic lesions
To test the role of central and peripheral noradrenergic systems in the
therapeutic action of antidepressants, we performed lesions of the nor-
adrenergic system. Chemical peripheral noradrenergic lesion was per-
formed 2 weeks before nerve injury using guanethidine monosulfate
(Sigma-Aldrich) with 5 daily intraperitoneal injections (30 mg/kg, 5 ml/
kg). For chemical denervation of spinal noradrenergic terminals, mice
were injected intrathecally, with 6-hydroxydopamine (6-OHDA; 20 g
per mouse, in 5l of 0.9% NaCl solution containing 100g/ml ascorbic
acid) under ketamine (68 mg/kg)/xylazine (10 mg/kg) intraperitoneal
anesthesia. For this intrathecal thoracic administration, the animal was
anesthetized, the skin of the back was shaved, and a 1 cm incision was
made near the insertion of the lower rib. A 27-gauge needle connected to
a 50 l Hamilton syringe was inserted into the intervertebral space be-
tween the thoracic T12 and lumbar L1 vertebrae. After the injection, the
needle was removed and the skin was sutured. A control group of non-
lesioned mice underwent the same procedure as the lesioned groups. At
end of the experiments (i.e., 5 weeks after sciatic nerve surgery), nerve-
injured and sham mice were deeply anesthetized with pentobarbital and
perfused intracardially with 4% paraformaldehyde in phosphate buffer
0.1 M (10 ml/min). Lumbar dorsal root ganglia (L4, L5, and L6) and
spinal cord were dissected, postfixed, cryoprotected, embedded in opti-
mal cutting temperature compound (Sakura Finetek), frozen, and cut
into 14-m-thick sections that were mounted on SuperfrostPlus slides
(Kindler). To evaluate tyrosine hydroxylase (TH) expression, we used
standardized procedures (Kaufling et al., 2010), incubating the sections
with a sheep anti-TH antibody (1:1000; Millipore, AB1542). The sections
were then incubated with secondary Cy3-conjugated donkey antibodies
(1:300; Jackson ImmunoResearch, 713–165-147). Sections were washed,
mounted with Vectashield, and viewed under a Nikon E80i microscope
with 10 and 20 objectives and images were acquired with an MBF
Bioscience camera CX9000 using Picture Frame acquisition software. A
separate set of animals with central or peripheral lesions was also studied
to control for noradrenaline and dopamine levels in the lumbar spinal
cord (see “Catecholamine quantification in the lumbar spinal cord” sec-
tion below).
Tissue and blood collection for molecular analysis
In separate experiments, dorsal root ganglia and/or lumbar spinal cord
were collected either after 3 weeks of chronic oral antidepressant treat-
ment or 120 min after acute administration of duloxetine for acute ex-
periments. Mice were killed by cervical dislocation, the back was
dissected, and a midline incision was done in the lumbar vertebrae to
extract the L4, L5, and L6 dorsal root ganglia ipsilateral to the surgery and
the lumbar spinal cord from L3 to L6. The three dorsal root ganglia were
pooled per animal and all tissue was quickly frozen and stored at80°C
until protein or RNA extraction.
For plasma assays of duloxetine, intracardiac blood collection was
performed in mice under deep general anesthesia (ketamine 68 mg/kg/
xylazine 10 mg/kg, i.p.) by inserting a needle in the left ventricle. Blood
was then collected and placed in blood collection tubes (Vacutainer, BD
Biosciences, 4 ml, #367526). The samples were then centrifuged (1500 g,
20°C, 15 min) and the plasma was collected and frozen at80°C.
Plasmatic levels of duloxetine
To compare duloxetine concentrations in neuropathic pain patients and
in the animal model, plasma levels were measured in animals either
under chronic duloxetine treatment or at 1, 2, 5, 10, or 24 h after acute
administration.
The human study received institutional ethics approval from the
Hoˆpitaux Universitaires de Strasbourg (France) and was performed in
accordance with the Declaration of Helsinki and its subsequent amend-
ments, good clinical practice, and all applicable regulatory requirements.
All patients provided written informed consent before their participation
in the study. The patients were identified by numbers.
The primary purpose was to evaluate residual plasmatic concentration
of duloxetine (i.e., before the morning intake) in patients relieved of at
least 30% of their neuropathic pain with duloxetine treatment (V0 visit).
The secondary purpose was to measure the plasmatic peak concentration
(i.e., 6 h after the morning intake; V1 visit) (Senthamil Selvan et al., 2007)
in the same patients.
At V0, the neuropathic characteristic of the pain was assessed with the
DN4 questionnaire (Bouhassira et al., 2005) and the etiology and loca-
tion of neuropathic pain was determined. The pain intensity reported by
the patient on a numeric rating scale with 11 points (Jensen and Karoly,
1992) was evaluated during the medical visits (V0 and V1) and concerned
the following: recall of pain intensity before the start of duloxetine treat-
ment, pain intensity experienced just before or when taking duloxetine at
V0, and pain intensity experienced 6 h after taking duloxetine at V1.
Sensation of improvement experienced by the patient was assessed on a
Patient Global Impression of Change in 7 points scale (Dworkin et al.,
2005). Patients’ inclusion criteria were as follows: treated with Cymbalta
(60 mg daily in one intake) for peripheral diabetic neuropathic pain or
for depression and associated with pain identified as neuropathic, report-
ing relief of at least 30% of their neuropathic pain since the initiation of
treatment, affiliated to a social security system, and having signed an
informed consent. Exclusion criteria were as follows: concomitant treat-
ment with enoxacin, fluvoxamine, flecainide, propafenone, metoprolol,
risperidone, verapamil, omeprazole, modafinil, mequitazine, tamoxifen,
and IMAO; necessary information could not be given to the patients;
pregnant or nursing women; nonmenopausal woman without effective
contraception; and patient under judicial protection, guardianship, or
curatorship. A total of eight patients were included.
Plasma and tissue measurements
Duloxetine quantification in the plasma of humans and animals. To com-
pare duloxetine concentrations in neuropathic pain patients and in the
animal model, plasma levels were measured by mass spectrometry. 10
pmol of D3-duloxetine internal standard (in which 3 atoms of hydrogen
1H have been substituted by 3 atoms of deuterium 2H; Alsachim) were
added to 200l of lithium– heparin plasma. Plasmas were acidified up to
2.5% v/v with formic acid (final volume of 800 l). After centrifugation
(20,000  g, 20°C, 15 min), the supernatant was submitted to a solid
phase extraction (SPE) using a positive pressure manifold (Thermo Elec-
tron). OASIS HLB SPE-cartridges (1 cm 3, 30 mg; Waters) were first
activated with 1 ml of acetonitrile (ACN) and then washed with 1 ml of
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H2O/formic acid 0.1% (v/v). The samples were loaded and the SPE car-
tridges were washed with 1 ml of H2O/formic acid 0.1% followed by 1 ml
of ACN 5%/formic acid 0.1% (v/v/v). The elution was performed with
500l of ACN 50%/H2O (v/v). Finally, eluted fractions were dried under
vacuum before MS analysis (see below).
Catecholamine quantification in the lumbar spinal cord. To control the
impact of the lesion procedures on catecholamines in the spinal cord, we
also quantified in a set of animals the noradrenaline and dopamine levels
in the lumbar spinal cord using mass spectrometry. Lumbar spinal cord
samples were homogenized with a tissue mixer (Bio-Gen PRO200 Ho-
mogenizer equipped with a 7 mm saw-tooth generator probe) in 200 l
of 0.5 M ascorbic acid. Homogenates were sonicated 10 s at 90 W and
centrifuged (18,000  g, 4°C, 15 min). Supernatant was recovered and
the concentration of proteins was determined (protein assay; Bio-Rad).
Then, 10 l of the extract was derived with the AccQ-Tag Ultra Deriva-
tization kit (Waters) according to the manufacturer. Briefly, 10 l of
samples were mixed with 35 l of the kit’s borate buffer and 10 l of
internal standards (10 pmol/standard; D4-dopamine, C6-noradrenaline;
Sigma-Aldrich and Alsachim). D4-dopamine corresponds to an internal
standard in which 4 atoms of hydrogen ( 1H) have been substituted by 4
atoms of deuterium ( 2H). C6-noradrenaline corresponds to an internal
standard in which 6 atoms of carbon ( 12C) have been substituted by 6
atoms of 13C. Then, 10l of AccQtag reagent was added and the reaction
medium was shaken 10 min at 55°C. After centrifugation (20,000  g,
20°C, 5 min), supernatant was subjected to a LC-MS/MS analysis.
LC-MS/MS instrumentation and analytical conditions
LC analyses were used to determine the presence of duloxetine or cat-
echolamines using the multiple reaction monitoring mode (MRM).
Analyses were performed on a Dionex Ultimate 3000 HPLC system
(Thermo Scientific) coupled with an Endura triple quadrupole mass
spectrometer (Thermo Electron). The system was controlled by Xcalibur
version 2.0 software (Thermo Electron). Dried samples (spinal cord ex-
tracts) were suspended in 100l of H2O/formic acid 0.1% (v/v) and 10l
of the solution was loaded onto an Accucore RP-MS column (ref 17626-
102130; 100  2.1 mm 2.6 m; Thermo Electron) heated at 35°C. For
derived samples, 10 l of the derivatization mixture was analyzed. Elu-
tions were performed by applying linear gradient of mobile phase A/B.
Mobile phase A corresponded to H2O 99.9%/formic acid 0.1% (v/v),
whereas mobile phase B was ACN 99.9%/formic acid 0.1% (v/v). A linear
gradient of 20 – 85% of mobile phase B at 400 l/min over 2.5 min was
applied followed by a washing step (0.5 min at 85% of mobile phase B)
and an equilibration step (1 min of 20% mobile phase B).
The MRM mode was performed at 3500 V of liquid junction voltage
and 292°C capillary temperature. The selectivity for both quadripoles Q1
and Q3 was set to 0.7 Da, which is the full width at half maximum of peak
height. The collision gas pressure of quadripole Q2 (collision chamber)
was set at 2 mTorr of argon. The selection of the monitored transitions
and the optimization of the collision energy (CE) were manually deter-
mined. In MRM mode, two mass analyzers (quadripoles Q1 and Q3)
were used as static mass filters to select particular precursor ions (parent
ions selected in quadripole Q1) and to monitor the particular fragments
(daughter ions, detected in quadripole Q3) produced after fragmenta-
tion in the collision chamber (quadripole Q2).
The respective parent ions, transitions and corresponding CE used for
MRM are as follow: for duloxetine, m/z 298.25¡m/z 123.75 (CE 42
eV), m/z 298.25 ¡ m/z 155.24 (CE  23 eV) and m/z 298.25 ¡ m/z
183.17 (CE  28 eV); for D3-duloxetine, m/z 301.25 ¡ m/z 123.75
(CE 40 eV), m/z 301.25¡m/z 157.12 (CE 7 eV) and 301.25¡m/z
183.05 (CE 27 eV); for AccQtag-dopamine, m/z 324.25¡m/z 171.10
(CE  33 eV); for AccQtag-D4-dopamine, m/z 328.25 ¡ m/z 171.10
(CE  35 eV); for AccQtag-noradrenaline, m/z 340.25 ¡ m/z
171.25 (CE 35 eV); for AccQtag-C6-noradrenaline, m/z 346.25¡m/z
171.25 (CE 27 eV).
The identification of the compounds was based on precursor ion,
selective fragment ions, and retention times obtained for duloxetine or
derived-catecholamine and the corresponding internal standard. Abso-
lute quantifications of the compounds were done using the ratio of
daughter ions response areas on the internal standards (isotope dilution
method).
siRNA experiments
2 adrenoceptor subtypes involved in acute effects of duloxetine were
identified using siRNA-mediated knock-down of adra2a and adra2c.
Knock-down of adra2a and adra2c mRNA were performed using
ACCELL siRNA (catalog #E-049576-00 and #E-043744-00, respectively)
designed and validated by Thermo Fisher/Dharmacon. A nontargeting
siRNA (catalog #D-001910-10-05) was used as a negative control. Stock
solutions for the targets and scrambled siRNA were prepared at 100M in
1 siRNA buffer (diluted from Dharmacon 5 siRNA buffer, catalog
#B-002000-UB-100). Targets and scrambled negative siRNA were in-
jected intrathecally (10 l per mouse) under gaseous anesthesia (isoflu-
rane 1.5–2%). Briefly, for lumbar intrathecal administration, a 27-gauge
needle connected to a 50 l Hamilton syringe was inserted between
the L5 and L6 vertebrae into the subarachnoidal space. Placement of the
needle was verified by the elicitation of tail flick movement. Time course
study was done with qRT-PCR to identify optimal time points for assess-
ing knock-down.
qRT-PCR
To verify the selectivity of the siRNAs, we quantified the expression of the
subtypes of the 2 adrenoceptors’ genes (adra2a, adra2b, and adra2c) in
lumbar spinal cord by qRT-PCR. Total mRNA was extracted using the
RNAeasy kit (Qiagen) and the cDNA was generated using the iScript
cDNA synthesis kit from Bio-Rad. qRT-PCR was performed on a Ther-
mocycler MylQ (Bio-Rad) using the Bio-Rad IQ Syber Green Supermix
assay. PCR consisted of an initialization step at 95°C for 3 min and the
amplification was realized for 40 cycles with denaturation at 95°C for
20 s, followed by annealing at 95°C for 20 s, and an extension at 60°C
for 20 s. All experiments were performed in duplicate sample deposits on the
amplification plate. The relative abundance of each RNA target gene tran-
script was normalized using endogenous control genes hypoxanthine-
guanine phosphoribosyltransferase (HPRT) and glyceraldehyde phosphate
dehydrogenase (GAPDH). Data were analyzed according to the standard
curve method. Primers have been designed using Oligo6.0 and M-fold soft-
wares based onMusmusculusmRNA sequences available in the NCBI data-
base and were as follows: musADRA2afw, CCAAGCTGCAAGATCAACGA
and musADRA2arev, TACGCACGTAGACCAGGATC; musADRA2bfw,
CAGAAGAAGGGGACTAGTGGG and musADRA2brev, GGCAGT
GTTTGGGGTTCACAT; musADRA2cfw, CCTACTGGTACTTCG
GGCAA and musADRA2crev, CCAGTAGCGGTCCAGACTAA.
Immunoblot analysis
To further explore the TNF-–NF-B pathway, whose gene expression
was globally enhanced in the dorsal root ganglia following nerve injury
and downregulated by chronic duloxetine treatment, we used the West-
ern blot technique. Total proteins were extracted in 150l of lysis buffer
(20 mM Tris pH 7.5; 150 mM NaCl; 10% glycerol; 1% NP-40; Protease
Inhibitor Cocktail; Roche), quantitated with Bio-Rad Protein Assay Dye
Reagent Concentrate and stored in Laemmli buffer (2% SDS; 25% glyc-
erol; 0.01% bromophenol blue; 0.125 M Tris, pH 6.8). Ten micrograms of
total protein from individual animals were resolved by 12% SDS-PAGE
under reducing conditions and then transferred to PVDF membrane (Im-
mobilon transfer membranes; Millipore, IPVH00010). The blots were incu-
bated for 1 h in blocking agent (ECL kit, GE Healthcare) overnight with
antibodies specific for TNF- (1:500, R&D Systems, AF-410-NA), TRAF
family member-associated NF-B activator (TANK) (1:1000; Cell Signaling
Technology, 2141), TLR2 (1:500; Abcam, ab108998), C-C motif chemo-
kine receptor like 2 (CCRL2) (1:500, Thermo Fisher Scientific, PA-
28743), or -tubulin (1:50000; Abcam, ab108342), followed by rabbit
anti-goat horseradish peroxidase (HRP)-conjugated secondary antibod-
ies (1:12000; Abcam, ab97100) or goat anti-rabbit HRP-conjugated sec-
ondary antibodies (1:10000; Millipore, AP307P), respectively. Blots were
revealed by chemiluminescence (ECL Prime Western Blotting Detection
Reagent, GE Healthcare, RPN 2232) using Hyperfilm (GE Healthcare,
RPN 1674K). Relative protein expression was determined using the den-
sitometry tool of Adobe Photoshop CS5 software. The bands were eval-
uated in grayscale, the background value was subtracted, and the ratio
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between the considered protein and -tubulin was calculated for each
sample.
RNA sequencing (RNA-Seq)
To go further in understanding the peripheral component of duloxetine
action, we conducted a transcriptomic analysis on dorsal root ganglia
using RNA-Seq.
Sample collection
Total RNA was extracted from dorsal root ganglia tissues with the Qiagen
RNeasy Mini Kit according to the manufacturer’s instructions. The qual-
ity of samples was verified using a bioanalyzer (Agilent Technologies,
2100), which uses a microcapillary-based electrophoretic cell, allowing
rapid and sensitive investigation of nucleic acid samples. The samples
were considered to be of high quality when their absorbance ratio 260/
280 was between 1.8 and 2. The stringent RNA quality was also controlled
using the bioanalyzer. The samples used for sequencing showed only two
distinct peaks for 18S and 28S rRNAs, with a ratio of 2 and an RNA
integrity number7.8. (Schroeder et al., 2006).
Library preparation and sequencing
RNA-Seq (Wang et al., 2009) libraries of polyadenylated RNAs were
prepared using Illumina TruSeq chemistry and were sequenced in
paired-end mode. For each sample, 250 ng of total RNA was used for
library preparation. Next-generation sequencing library preparation was
performed on the Beckman Biomek FX using the Illumina TruSeq RNA
Sample Preparation Kit version 2 and the Illumina TruSeq LT DNA
adapters according to manufacturer’s protocol (TruSeq RNA Sample
Preparation version 2 Guide) at the EMBL Genecore. The procedure
included the isolation and fragmentation of polyadenylated RNA, syn-
thesis of double-stranded cDNA, end repair, A-tailing, and ligation of
sequencing adaptors and a final PCR amplification step. Resulting RNA-
Seq libraries were sequenced on an Illumina Hiseq2500 at a read length of
50 bp in paired-end mode. RNA-Seq was performed for n 3 biological
replicates per group.
Bioinformatics analyses
The bioinformatic processing of RNA-Seq data was done as described
previously (Maussion et al., 2015; Farmer et al., 2016; Lutz et al., 2017)
using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/
links.html) and Trimmomatic (Bolger et al., 2014) for adapter trimming
from raw read sequences; Bowtie2 and TopHat2 (Trapnell et al., 2009)
for alignment of trimmed reads to the reference mouse genome; HTSeq-
count for gene counting; and DESeq2 (Love et al., 2014) for differential
expression analysis.
Alignment. Following the high-throughput sequencing, 50 bp
paired-end reads were aligned to the mouse reference genome
(mm10) using Bowtie2 and TopHat version 2.1.0 (http://ccb.jhu.edu/
software/tophat/index.shtml) with the following parameters: a mate
insert distance of 75 bp and a fr-unstranded library type because
our library preparation protocol does not conserve information re-
garding strand (see illumina.com/documents/products/technotes/
RNASeqAnalysisTopHat.pdf). The reads that reached mapping qual-
ity of 50 under the TopHat2 software (i.e., that map to a unique
location in the reference genome) were used for gene quantification.
Quantification. Genes were first annotated based on the Ensembl an-
notation database (Ensembl release 75, GRCm38). To quantify gene ex-
pression level, we then used HTSeq-count version 0.6.1p1 (http://htseq.
readthedocs.io/en/release_0.10.0/) to count the number of reads that
overlapped the genes identified in the aforementioned annotation
(Anders et al., 2015). To attribute or not each read to a given gene,
including when overlaps with two genes were present, we used
HTSeq-count under the intersection-nonempty mode (https://htseq.
readthedocs.io/en/master/count.html). The results were then com-
bined to form a count matrix, providing expression level for each gene
in each biological sample.
Differential expression analysis. Genes with an absence of mapped read
were removed from the analysis. Furthermore, genes with low counts
were also removed from the analysis by keeping only those that had at
least 20 counts per sample in average. The differential expression analysis
to compare expression level between experimental groups was performed
using the DESeq2 generalized linear model to conduct pairwise comparisons
(e.g., saccharin-cuff/saccharin-sham, duloxetine-cuff/saccharin-cuff, etc.).
For functional analyses, we used the DAVID website (DAVID Bioin-
formatics Resources 6.7, National Institute of Allergy and Infectious
Diseases–National Institutes of Health; https://david.ncifcrf.gov/), and
the Gene Set Enrichment Analysis software (GSEA, version 2.2.0, The
Broad Institute/Massachusetts Institute of Technology). The DAVID
Bioinformatics Resources was one of the earliest bioinformatics tools for
functional analyses of large gene lists, which are usually obtained from
genome-wide studies (da Huang et al., 2009). It relies on the focus on
specific sets of genes; that is, groups of genes that are known to share
common biological function. However, such analysis is based on the list
of genes displaying significant expression changes, which is dependent
upon the significance threshold chosen for differential expression (here,
p  0.01). GSEA is another analytical method for interpreting gene ex-
pression data by using their ranking as a function of fold changes across
experimental groups (upregulation/downregulation) (Subramanian et
al., 2005). The GSEA method is independent from the choice of a signif-
icance threshold, and makes it possible to calculate an enrichment score
(ES) that reflects the degree of overrepresentation of a group of genes that
belong to a specific signaling pathway and are enriched in down- or
upregulated genes.
Experimental design and statistical analysis
The global design of all experiments is described in Figure 1. Data were
collected in a blinded manner to avoid bias. Minimum sample sizes were
estimated from previously published datasets with similar experimental
parameters. All statistical tests, except for genomic analyses, were per-
formed using STATISTICA 12 software (Statsoft). Sigma-Plot 12.5 soft-
ware (Systat Software) was used to generate the graphs. Results in all
graphs are presented as mean  SEM. Individual data were overlapped
on bar graphs concerning duloxetine dosage (see Fig. 6) and immuno-
blotting (see Figs. 8, 9, 11).
Behavioral experiments. Experiments were conducted either in males
only (see Figs. 2, 3, 4A–D, 5B,C, 6A, 8D–F, 9C, 10A–E, H ) or in an equal
number of males and females per experimental group (see Figs. 4E,F,
5A,D, 10F,G). The numbers of animals in each experimental group is
provided both in graphs (in brackets) and in the extended data tables
supporting each figure. Statistical analyses for behavioral studies were
performed using multifactor ANOVA. The surgery procedure (sham or
cuff) and the various treatments were taken as between-group factors.
When needed, the time of measurement was taken as a within-subject
factor. The Duncan test was used for post hoc comparisons. For the com-
parison of mechanical sensitivity thresholds before and after noradren-
ergic antagonist (see Figs. 4A, D, 10E) or opioidergic antagonist (see Fig.
5B) and siRNA (see Fig. 4C) administrations in duloxetine-related ex-
periments, we used one-way ANOVA and the Duncan test for post hoc
comparisons. The significance level for all aforementioned analyses was
set at p  0.05 and the exact p-values are provided down to 0.001. De-
tailed information on the number and sex of animals in each experimen-
tal group, the statistical tests that were used, and the statistical results is
given in the extended data tables that support each figure (Fig. 2-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f2-1; Fig. 3-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f3-1; Fig. 4-1, available
at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f4-1; Fig. 5-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f5-1; Fig. 8-1, available
at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f8-1; Fig. 9-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f9-1; and Fig. 10-1, avail-
able at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f10-1).
Dosage, immunoblotting, and qRT-PCR experiments. Behavioral readout
of the experiments was evaluated before sampling for data reported in Fig-
ures 3, 6, 8, 9, and 11. Experiments were conducted in males for Figures 3B,
4B, 6, 8A, C, F, 9A, B, and 11 and in females for Figure 8B. The numbers of
animals in each experimental group is provided both in graphs (in brackets)
and in the extended data tables supporting each figure. After calculating the
ratio between the target protein and -tubulin, immunoblotting data for
each animal was expressed as the fold change from the mean of the corre-
sponding control group (see Figs. 8, 9, 11) and statistical analyses were per-
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formed using the nonparametric Kruskal–Wallis test, followed by multiple
comparisons with the Wilcoxon test. qRT-PCR data (Fig. 4B) were also
analyzed using the nonparametric Kruskal–Wallis test, followed by multiple
comparisons with the Wilcoxon test. The relation between duloxetine
plasma levels and behavioral response (Fig. 6A) was tested for statistical
correlation. The significance level for all aforementioned analyses was set at
p 0.05 and the exact p-values are provided down to 0.001. Detailed infor-
mation on the number of animals in each experimental group and their sex,
on the statistical tests that was used, and the statistical results, is given in the
extended data tables that support each figure (Fig. 4-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.2018.f4-1; Fig. 8-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f8-1; Fig. 9-1, available
at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f9-1; and Fig. 10-1,
available at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f10-1).
RNA-Seq experiments. Neuropathic pain was induced by inserting a
cuff around the main branch of the sciatic nerve. Chronic oral duloxetine
treatment started at least 2 weeks after surgery and lasted for 3 weeks. The
presence and relief of mechanical allodynia were tested using von Frey
filaments. L4, L5, and L6 dorsal root ganglia were collected for molecular
analysis. RNA sequencing was performed on n 3 biological replicates
per group. A differential expression analysis was performed using the
DESeq2 generalized linear model to conduct pairwise comparisons with
significance level set at p  0.01. Statistics for functional analyses were
conducted using the DAVID website and using GSEA software and in-
cluded the multiple testing corrections implemented by each type of
software.
Results
Oral duloxetine displays acute and delayed
anti-allodynic actions
In a model of neuropathic pain induced by sciatic nerve compres-
sion (Benbouzid et al., 2008a; Yalcin et al., 2014), we first established
the dose–response curve of oral duloxetine leading to an acute anti-
allodynic action. This acute duloxetine treatment was done at least 2
weeks after the surgical procedure. 20 mg/kg was necessary to ob-
serve partial relief and 30 mg/kg to reach full relief within 120 min
(F(6,120) 5.5, p 0.001) (Fig. 2A and Fig. 2-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.2018.f2-1; detailed statistics
for all results are given in extended data tables supporting figures).
This rapid but transitory allodynia relief was observed in the absence
of analgesic action in control animals (Fig. 2B). Although such rapid
action is not observed clinically, it could be postulated that the un-
derlying mechanism may recapitulate the one observed after pro-
longed treatment. We also established a dose–response curve of
chronic oral duloxetine provided through drinking water. This
chronic duloxetine treatment began at least 2 weeks after the surgical
procedure. Under this delivery protocol, allodynia relief required a
few days of treatment, with partial effect at 100g/ml and full recov-
ery at 150 and 200 g/ml (F(9,216)  2.9, p  0.001) (Fig. 2C and
Fig. 2-1, available at https://doi.org/10.1523/JNEUROSCI.1004-
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Figure 2. Characterization of the effect of acute and chronic oral duloxetine treatments on mechanical allodynia in mice. PWTs were assessed using von Frey filaments. Neuropathic pain was
induced by inserting a cuff around themain branch of the sciatic nerve at least 2 weeks before the start of duloxetine treatment. A, Mice with a cuff around the right sciatic nerve received an acute
per os administration of duloxetine (Dul; 15, 20, or 30 mg/kg) or water with saccharin (Sacch; 0.2%). Duloxetine displayed a transitory and ipsilateral anti-allodynic action at the highest dose
(30mg/kg).B, The30mg/kgduloxetinedidnot affectmechanical PWTof shammice.C, For chronic treatment, duloxetine (50, 100, 150, or 200g/ml)wasdelivered in thedrinkingwaterwith0.2%
saccharin. This treatment dose-dependently suppressed the cuff-induced mechanical allodynia. No effect of duloxetine was observed on the contralateral paw. D, Chronic oral duloxetine
(200 g/ml) had no influence on the PWT of sham mice. E, Histogram showing the equivalence between g/ml and mg/kg/d for duloxetine based on fluid consumption from animals with
behavioral data displayed in C. For all graphs, data are expressed as mean SEM. n are given in brackets. “B” (for baseline) corresponds to the PWT before surgery, chronic treatment start and
duration are indicated by the dotted and the thick lines in C and D. Detailed statistics are provided in Figure 2-1, available at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f2-1.
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18.2018.f2-1). Here again, the allodynia relief was observed in the
absence of analgesic action in control animals (Fig. 2D). The dose
necessary to full relief corresponded to 20 mg/kg/d, with an intake
spread over the animal’s daily drinking period (Fig. 2E). We then
used those acute and prolonged treatment procedures to compare
their respective mechanisms.
Acute and prolonged duloxetine treatments recruit distinct
sources of noradrenaline
Clinically, selective serotonin reuptake inhibitors such as fluox-
etine are poorly effective against neuropathic pain even though
they demonstrate efficacy against depression (Sindrup et al.,
2005). This suggests a critical role of the noradrenergic system in
pain relief. Here, we tested the respective role of two sources of
noradrenaline: the central descending pathways and the periph-
eral fibers. We selectively lesioned the former by delivering the
6-OHDA toxin intrathecally at thoracic level on the path of de-
scending noradrenergic fibers. This procedure resulted in a loss
of TH-positive fibers in the dorsal horn of the spinal cord (Fig.
3A) and a decrease in lumbar noradrenaline (F(3,29)  76.6, p 
0.001), but not dopamine (F(3,29)0.4,p0.74), levels (Fig. 3B and
Fig. 3-1, available at https://doi.org/10.1523/JNEUROSCI.1004-
18.2018.f3-1). Following such lesion, duloxetine lost its capacity to
acutely relieve neuropathic allodynia (F(2,24)13.8,p0.001) (Fig.
3C and Fig. 3-1, available at https://doi.org/10.1523/JNEURO-
SCI.1004-18.2018.f3-1), whereas the delayed anti-allodynic action
of chronic duloxetine was preserved (F(9,153)  8.8, p  0.001)
(Fig. 3D and Fig. 3-1, available at https://doi.org/10.1523/
JNEUROSCI.1004-18.2018.f3-1).
The peripheral sympathetic sprouting in the dorsal root ganglia
that accompanies peripheral nerve injury (McLachlan et al., 1993;
Ramer and Bisby, 1998; Bohren et al., 2013) was suppressed by pe-
ripheral injection of guanethidine, a toxin that does not cross the
blood–brain barrier and thus spares the central noradrenergic sys-
tem (Fig. 3A). Although the lesion suppressed noradrenergic sprout-
ing in the dorsal root ganglia, the local TH-expressing neurons
(Brumovsky, 2016) that are mostly C-low-threshold mechanorecep-
tors (and might be dopamine neurons) were not affected by the
toxin (Fig. 3A). This lesion of peripheral noradrenergic fibers did not
prevent the capacity of acute duloxetine at high dose to rapidly alle-
viate allodynia (F(2,34) 6.2, p 0.001) (Fig. 3C and Fig. 3-1, avail-
able at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f3-1),
but it abolished the delayed anti-allodynic action of chronic dulox-
etine (F(9,162)  6.7, p  0.001) (Fig. 3D and Fig. 3-1, available
at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f3-1). These
findings support the idea that different anatomical substrates under-
lie the acute and delayed actions of duloxetine in a neuropathic pain
context.
Acute and prolonged duloxetine treatments recruit
different adrenoceptors
By blocking the reuptake site, duloxetine increases levels of nor-
adrenaline, which then acts on adrenoceptors to exert its effects.
The 2 adrenoceptor is a family of three receptors, 2A, 2B, and
2C, all products of three different genes. Two of them, 2A and
2C, are preferentially expressed in the dorsal horn of the spinal
cord and implicated in nociceptive controls (Pertovaara, 2006).
On the other hand, 2 adrenoceptors are present on non-
neuronal satellite cells of the dorsal root ganglia and have been
shown previously to be important to the anti-allodynic action of
chronic nortriptyline (Bohren et al., 2013). An antagonist of 2
adrenoceptors, yohimbine, prevented acute duloxetine action
(F(1,16)  15.3, p  0.001) (Fig. 4A and Fig. 4-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f4-1). We
then used RNA interference to identify the respective role of 2A
and 2C in duloxetine action. The selectivity of siRNAs delivered
intrathecally was first verified in vivo (2A-AR: H2,23 15.15, p
0.001; 2B-AR: H2,23 2.4, p 0.3; 2C-AR: H2,23 15.37, p
0.001) (Fig. 4B and Fig. 4-1, available at https://doi.org/10.1523/
JNEUROSCI.1004-18.2018.f4-1). Local knock-down of 2A, but
not 2C, adrenoceptors suppressed the acute duloxetine action,
pointing to a preferential involvement of 2A receptors (F(1,28)
20.1, p 0.001) (Fig. 4C and Fig. 4-1, available at https://doi.org/
10.1523/JNEUROSCI.1004-18.2018.f4-1). In contrast, yohim-
bine, even when given chronically, had no influence on the delayed
action of chronic duloxetine (Fig. 4D), whereas this action was
blocked by chronic propranolol, an antagonist of  adrenoceptors
(F(1,16) 10.6, p 0.001) (Fig. 4D and Fig. 4-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.2018.f4-1), and was lost in
2 adrenoceptor-deficient (2-AR
/) mice (F(8,120)  3.6, p 
0.001) (Fig. 4E, left, and Fig. 4-1, available at https://doi.org/10.1523/
JNEUROSCI.1004-18.2018.f4-1), whether male or female (2-
AR	/	 male mice: F(8,72)  6.9, p  0.001; 2-AR
	/	 female
mice: F(8,72) 2.6, p 0.003; 2-AR
/male mice: F(8,48) 3.6,
p 0.001; 2-AR
/ female mice: F(8,48) 2.1, p 0.027) (Fig.
4E, right, and Fig. 4-1, available at https://doi.org/10.1523/
JNEUROSCI.1004-18.2018.f4-1). Interestingly, the acute action
of duloxetine at high dose remained present in 2-AR
/ mice
(Fig. 4F) and was not affected by propranolol (Fig. 4A). These
data show that the acute transitory allodynia relief is mediated by
an action of noradrenaline on 2A adrenoceptors, whereas the
delayed action is mediated by 2 adrenoceptors.
Acute and prolonged duloxetine treatments recruit different
opioid receptors
The opioid system, via MOR, DOR, and KOR, plays a crucial role
in the inhibitory control of pain (Gave´riaux-Ruff and Kieffer,
2002; Dierich and Kieffer, 2004) and different studies have pro-
vided evidence for an involvement of the opioid system in the action
of antidepressants on neuropathic pain (Kremer et al., 2016a). Acute
duloxetine remained effective in KOR/mice, but lost its action in
MOR/ and in DOR/mice (MOR/: F(2,30) 5.6, p 0.002;
DOR/: F(2,30) 5.0, p 0.003) (Fig. 5A and Fig. 5-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f5-1). The in-
volvement of opioid receptors was also confirmed pharmacologi-
cally by blocking acute duloxetine action with naloxone (Acute Dul
Acute NLX: F(1,15) 19.5, p 0.001) (Fig. 5B and Fig. 5-1, available
at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f5-1). More-
over, MOR and DOR implicated in acute duloxetine action are
likely central because the peripheral antagonists naloxone me-
thiodide and methylnaltrexone did not reverse the acute anti-
allodynic action of duloxetine (Acute Dul Acute NLX Meth:
F(1,21) 19.0, p 0.001; Acute Dul Acute MNTX: F(1,15) 19.3,
p  0.001) (Fig. 5B and Fig. 5-1, available at https://doi.org/
10.1523/JNEUROSCI.1004-18.2018.f5-1). In contrast, after nal-
oxone methiodide administration, mechanical allodynia reappeared
in nerve injured mice chronically treated with duloxetine, thus
pointing to the involvement of peripheral opioids (Chronic Dul
Acute NLX Meth: F(3,39)  7.1, p  0.001) (Fig. 5C and Fig. 5-1,
available at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f5-
1). In this case, chronic treatment remained effective in MOR/
and KOR/ mice, but lost its action in DOR/ mice (DOR/:
F(8,120) 3.8, p 0.001) (Fig. 5D and Fig. 5-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.2018.f5-1). These data show
that the long-term action of duloxetine depends on the presence of
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peripheral DOR, whereas acute effect at high dose requires central
MOR and DOR.
Duloxetine plasma levels in patients are similar to those
obtained in mice under prolonged treatment
Together, the previous findings highlight two independent
mechanisms for duloxetine, both starting with the recruitment of
noradrenaline: an acute transitory anti-allodynic action depend-
ing on the central noradrenergic descending pathways mediated
by 2A adrenoceptors and requiring the presence of central MOR
and DOR; and a delayed anti-allodynic action peripherally medi-
ated and involving 2 adrenoceptors and DOR. Recent work also
reported that this delayed action of duloxetine in the animal
model persists for a few days after cessation of the chronic treat-
ment (Salvat et al., 2018). These results raised the question of the
mechanism(s) present in neuropathic pain patients chronically
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Figure 3. Noradrenergic substrate for the anti-allodynic action of duloxetine. Right PWTs were assessed using von Frey filaments. Lesions of noradrenergic pathways were done 2 weeks before
the surgeries to induce neuropathic pain. Neuropathic pain was induced by inserting a cuff around the main branch of the sciatic nerve at least 2 weeks before the start of duloxetine treatment. A,
TH immunostaining in the lumbar dorsal root ganglia (DRG; scale bars, 35m) and in the laminae II–III of the lumbar spinal cord (scale bars, 60m). Intrathecal 6-OHDA (central lesion, 20g, i.t.)
allowed lesioning the noradrenergic descending pathways (green arrows: examples of fibers), whereas guanethidine (peripheral lesion, 30 mg/kg, i.p.) allowed lesioning the sympathetic fiber
sprouting in the DRG, which is consecutive to nerve injury (white arrows: examples of fibers). B, Monoamine levels, measured by mass spectrometry, in the lumbar spinal cord confirmed that
intrathecal 6-OHDA significantly reduced spinal noradrenaline levels. n values are given in brackets. **p 0.01 comparedwith other groups. C, Acute administration of duloxetine at high dose (30
mg/kg p.o.) induced a rapid anti-allodynic effect (top graph), which was suppressed by a central noradrenergic lesion (middle graph), but not by a peripheral lesion (bottom graph). D, Chronic
duloxetine treatment (200g/ml) exerted a delayed anti-allodynic effect (top graph), which was suppressed by the peripheral noradrenergic lesion (bottom graph), but not by the central lesion
(middle graph). Dul, Duloxetine; Sacch, saccharin. For all graphs, data are expressed as mean SEM. “B” corresponds to the PWT before surgery; “acute n/chronic n” are given in brackets, chronic
treatment start and duration are indicated by the dotted and the thick lines in D. *p 0.05, ***p 0.001 compared with sham saccharin groups, one-way ANOVA was used for B, ANOVA with
repeated measures for C and D. Detailed statistics are provided in Figure 3-1, available at https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f3-1.
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Figure 4. Role of the and adrenoceptors in the anti-allodynic action of duloxetine. Right PWTs were assessed using von Frey filaments. Neuropathic pain was induced by inserting a cuff
around themain branch of the sciatic nerve at least 2weeks before the start of duloxetine treatment.A, In nerve-injuredmice, chronic yohimbine (2 adrenoceptor antagonist, 20g/ml in drinking
water for 5 d), but not chronic propanolol ( adrenoceptor antagonist, 50g/ml in drinking water for 5 d), prevented the acute action of a high dose of duloxetine (30 mg/kg p.o.; n are given in
brackets, *p 0.05 compared with time before acute administration). B, Selective decrease in mRNA expression was observed in nerve-injured mice 72 h following siRNA intrathecal delivery (1
nmol; n 6–8mice/group, **p 0.01 comparedwith scramble Groups). GOI, gene of interest. C,2A, but not2C, adrenoceptor knock-down by siRNA suppressed the acute effect of duloxetine
(n values are given in brackets, *p 0.05 comparedwith time before acute administration).D, In nerve-injuredmice, chronic propranolol but not chronic yohimbine suppressed the anti-allodynic
action of chronic duloxetine (200g/ml, n values are given in brackets, *p 0.05 comparedwith time before antagonist administration or to sham saccharin groups). The two graphs on the right
display the detailed time course of the experiment summarized on the left. In the time course graphs, duloxetine was provided from the first day of treatment and the start and duration of the
antagonist cotreatment are indicated by the dotted and the thick lines. E, In2-AR	/	mice, chronic oral duloxetine (200g/ml) suppressed the ipsilateral allodynia but remained ineffective in
2-AR/ mice. The left graphs display data from all 2-AR	/	 and 2-AR/ mice, whereas the right graphs present results separately in males and females. (Figure legend continues.)
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treated with duloxetine. We thus used mass spectrometry to
compare drug plasma levels in duloxetine-treated mice and pa-
tients. In mice with nerve injury, plasmatic levels of acutely de-
livered duloxetine were directly correlated over time to the PWT
(r  0.90, p  0.001; Fig. 6A). A full relief from neuropathic
allodynia was observed 2 h after duloxetine administration
(F(1,55) 39.6, p 0.001) (Fig. 6A), corresponding to plasmatic
concentrations of 5700  600 nM (Fig. 6A). However, plasma
levels of duloxetine in nerve injured mice receiving prolonged
treatment and displaying full relief from allodynia were in the
range of a few hundred nanomolar (376 65 nM on the morning,
453  46 nM on the evening), which is 12 times lower than
observed for the acute procedure (Fig. 6B). In patients from var-
ious neuropathic etiologies and partially relieved from neuro-
pathic pain by chronic duloxetine treatment (60 mg once a day)
(Table 1), the plasmatic peak concentration was 297  61 nM,
whereas the residual plasmatic levels before morning duloxetine
intake was 119 23 nM (Fig. 6B). These plasma concentrations in
patients were comparable to those measured in animals under
prolonged treatment, which highlights the potential relevance of
the peripheral mechanism of duloxetine action.
Peripheral nerve injury leads to a remodeling of dorsal root
ganglia, whereas prolonged duloxetine treatment has an
anti-neuroimmune effect
To go further in understanding this peripheral component of
duloxetine action, we conducted a transcriptomic analysis using
RNA sequencing. Following 5 weeks of nerve injury, we still ob-
served significant changes in the expression of 193 genes in the
dorsal root ganglia, with two-thirds of them being upregulated
(Fig. 7A). The DAVID functional analysis showed that these mo-
lecular changes correspond to a remodeling of the dorsal root
ganglia, with a particular impact on the extracellular matrix, in-
tegrin signaling, and cell differentiation (Fig. 7B). Conversely,
half as many genes were significantly affected by chronic dulox-
etine treatment, with two-thirds of them downregulated (Fig.
7C). The functional analysis showed that duloxetine primarily
affected neurogenic inflammation, as reflected by the presence of
genes regulating inflammation via immune response or cytokine
response (Fig. 7D). The impact of chronic duloxetine on neuro-
genic inflammation is further supported by GSEA. Indeed, sig-
nificant enrichment of TNF- signaling via NF-B was observed
4
(Figure legend continued.) F, Acutely, a high dose of duloxetine (30 mg/kg, p.o.) suppressed
mechanical allodyna in both2-AR	/	 and2-AR/mice. Dul, Duloxetine; Sacch, saccha-
rin. Data are expressed as mean SEM. “B” corresponds to the mechanical threshold sen-
sitivity of right paw before surgery. AR, Adrenoceptor; “2-AR	/	 n/2-AR/ n” are
given in brackets. *p 0.05 compared with sham saccharin groups, one-way ANOVA was
used for A and C and D, Kruskal–Wallis test for B and ANOVA with repeated measures for
D–F. Detailed statistics are provided in Figure 4-1, available at https://doi.org/
10.1523/JNEUROSCI.1004-18.2018.f4-1.
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following nerve injury (ES  0.42, p  0.00001) (Fig. 7E),
whereas chronic duloxetine downregulated gene expression as-
sociated to this pathway (ES  0.34, p  0.002) (Fig. 7E).
Although few of the nerve-injury-related individual genes were
significantly altered by the treatment, chronic duloxetine mostly
blunted the overexpression and underexpression of half of all
these genes. Therefore, only 41.9% of the nerve injured-related
genes still displayed significant changes following chronic dulox-
etine treatment (Fig. 7F).
Prolonged duloxetine treatment displays an indirect
anti-TNF- action
Nerve injury has been shown to overexpress the membrane
bound (26 kDa) TNF- (mTNF-) in the lumbar dorsal root
ganglia, which can be corrected by nortriptyline (Bohren et al.,
2013). Here, we confirmed such overexpression of mTNF- in male
mice and showed that it can be dose-dependently corrected by
chronic duloxetine treatment (H(3,35)  15.8, p  0.001) (Fig. 8A
and Fig. 8-1, available at https://doi.org/10.1523/JNEUROSCI.1004-
18.2018.f8-1). We also found similar results in female mice (H(2,21)
 7.6, p 0.022) (Fig. 8B and Fig. 8-1, available at https://doi.org/
10.1523/JNEUROSCI.1004-18.2018.f8-1). Interestingly, 2 h after
acute administration of duloxetine, at the peak of the acute anti-
allodynic action, this anti-TNF- effect was not present at protein
level (H(2,21)  6.7, p  0.034) (Fig. 8C and Fig. 8-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f8-1), which
further highlights that different mechanisms underlie acute versus
chronic action of the drug.
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Figure 6. Duloxetine plasma concentrations in mice and in human patients. In mice, right PWTs were assessed using von Frey filaments and neuropathic pain was induced by inserting a cuff
around the main branch of the sciatic nerve at least 2 weeks before the start of duloxetine treatment. Dosage in the clinical setting was done on neuropathic pain patients chronically treated with
duloxetine (Cymbalta, 60 mg daily in one intake) and reporting relief of at least 30% of their neuropathic pain since the initiation of the treatment. Duloxetine plasma concentrations were
determined using mass spectrometry. A, Comparison of mean plasma concentration–time profile and behavioral data for acute duloxetine oral administration in mice (30 mg/kg, p.o.; n 7 or 8
per each time point). The insert shows the correlation between duloxetine plasma levels and PWT for animals with detectable duloxetine plasma levels (time points from 1 to 24 h, n 38 total).
B, Mean plasma concentration of duloxetine 2 h after acute oral administration (30mg/kg, p.o.) and after a chronic oral treatment (200g/ml, 3weeks) inmice, aswell as 6 h (peak) after the daily
intake of the chronic treatment (60mg per day) or in themorning (residual) just before duloxetine intake, in patients with neuropathic pain. Data are expressed asmean SEM. n values are given
in brackets. ND, Nondetectable.
Table 1. Characteristics of patients included in the duloxetine plasma dosage study
Patient ID Gender Age (y) Weight (kg) Etiology of NP Location of NP Concomitant treatments
01 F 68 80 Traumatic C7
02 F 52 75 Traumatic L3
03 F 51 55 Traumatic C7
04 F 43 55 Traumatic C7
05 M 66 76 Diabetic Lower limbs Baclofen 10 mg
06 F 43 60 Stroke Left hemibody
07 M 30 70 Traumatic S1
08 F 46 65 Traumatic C6
Treatment
duration
NRS before duloxetine
treatment
NRS after duloxetine
treatment V0
NRS after duloxetine
treatment V1 PGIC
Residual plasma level
V0 (nM)
Peak plasma level
V1 (nM)
01 3 mo 7 4 4 2 96.49 167.96
02 1 y 6 2 1 1 76.57 122.4
03 5 mo 8 4 4 2 261.28 591.06
04 6 mo 8 4 4 2 73.72 414.3
05 1 y 8 1 1 1 120.86 444.37
06 2 mo 4 2 2 3 137.54 202.28
07 6 mo 8 4 4 2 52.11 118.36
08 1 mo 9 3 3 1 134.51 312.75
NP, Neuropathic pain; NRS, numeric rating scale; PGIC, patients’ global impression of change; V0, visit before the morning drug intake; V1, visit 6 h after the morning drug intake.
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Figure 7. Impact of nerve injury and chronic duloxetine treatment on dorsal root ganglia transcriptome. Neuropathic pain was induced by inserting a cuff around the main branch of
the sciatic nerve. Chronic oral duloxetine treatment started at least 2 weeks postsurgery and lasted for 3 weeks. The presence and relief of mechanical allodynia were tested using von
Frey filaments. L4, L5, and L6 dorsal root ganglia were collected for molecular analysis. A, Representation of genes significantly upregulated (red) and downregulated (blue) in dorsal root
ganglia following sciatic nerve injury. The numbers above the graphs indicate the number of genes that showed significant changes in expression. B, Based on the analysis using the
DAVID Bioinformatics Resources (which consider sets of genes known to be functionally related), the table shows the top functional changes concerning gene expression in the dorsal root
ganglia following nerve injury. The function annotations are the one identified under DAVID analysis; only the five highest p-value functional changes are displayed, examples of genes
with significant differential expression and belonging to the functionally related gene list are provided. C, Representation of genes significantly upregulated (red) and downregulated
(blue) in dorsal root ganglia following long-term duloxetine treatment. The numbers above the graphs indicate the number of genes that showed significant changes in expression. D,
Based on DAVID analysis, the table shows the top functional changes concerning gene expression in the dorsal root ganglia following long-term duloxetine treatment in mice with
neuropathic pain. E, At the gene expression level, peripheral nerve injury induced an upregulation of the TNF- signaling via NF-B, whereas chronic duloxetine downregulated this
signalization, as shown by GSEA. In these graphs, the x-axis represents the distribution of genes, from the most strongly upregulated to the most strongly downregulated (“gene
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We then explored whether the anti-TNF- action or an
inhibition of the NF-B pathway would be relevant to neuro-
pathic pain relief. We first tested the clinically used anti-
TNF- biotherapies certolizumab and adalimumab on
neuropathic allodynia. Both drugs suppressed this symptom
at each administration (certolizumab: F(13,156)  4.7, p 
0.001; adalimumab: F(13,156)  5.3, p  0.001) (Fig. 8D and
Fig. 8-1, available at https://doi.org/10.1523/JNEURO-
SCI.1004-18.2018.f8-1) in nerve-injured animals, but had no
analgesic action in control animals (Fig. 8E). Because TNF-
recruitment was accompanied by a recruitment of the NF-B
pathway, we also tested its implication by treating the mice
with the NF-B pathway inhibitor PDTC, which suppressed
both the nerve-injury-induced increase in mTNF- (H(2,18)
11.5, p  0.003) (Fig. 8F and Fig. 8-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.2018.f8-1) and the
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mechanical hypersensitivity (F(5,90) 7.7, p  0.001) (Fig. 8F
and Fig. 8-1, available at https://doi.org/10.1523/JNEUROSCI.
1004-18.2018.f8-1).
Prolonged duloxetine treatment affects different members of
TNF-–NF-B pathway
In addition to this direct assessment of treatment impact on
TNF-, we further explored some members of the TNF-–
NF-B pathway, the gene expression of which was globally en-
hanced following nerve injury and downregulated by chronic
duloxetine treatment: TANK, CCRL2, and TLR2. All three proteins
were overexpressed in the lumbar dorsal root ganglia of nerve in-
jured mice, which was reversed by chronic duloxetine treatment
(TANK: H(2,20)  3.2, p  0.02; CCLR2: H(2,20)  5.7, p  0.04;
TLR2: H(2,20)  5.1, p  0.046) (Fig. 9A and Fig. 9-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f9-1) and we
showed that the action of duloxetine on TLR2 expression was depen-
dent upon 2 adrenoceptors (2-AR
/ mice: H(2,26)  8.3, p 
0.015) (cf. Fig. 9B and A; Fig. 9-1, available at https://doi.org/
10.1523/JNEUROSCI.1004-18.2018.f9-1). To address the relevance
of TLR2 to neuropathic pain relief, we then tested the TLR2/TLR4
antagonist RS-LPS (Lu et al., 2013) and the more selective neutral-
izing anti-TLR2 antibody mAb T2.5 (Meng et al., 2004) and showed
that they both have an anti-allodynic effect (RS-LPS: F(6,96)  4.8,
p  0.001; T2.5: F(7,84)  4.0, p  0.001) (Fig. 9C and Fig. 9-11,
available at https://doi.org/10.1523/JNEUROSCI.1004-18.
2018.f9-1).
Acute and prolonged amitriptyline treatments recruit
different mechanism
We identified two independent mechanisms by which duloxetine
can relieve neuropathic pain. To generalize these findings, we
tested a representative of another family of antidepressant drugs,
the tricyclic antidepressant amitriptyline, which is also prescribed
as a first-line treatment for neuropathic pain. For delivery, we
used either intraperitoneal administration or oral administration
after establishing the dose–response curve of acute (Fig. 10A,B) and
chronic (Fig. 10C) actions. As observed for duloxetine, the lesion of
descending noradrenergic pathways suppressed the capacity of acute
(but not chronic) amitriptyline to relieve neuropathic allodynia
(acute: F(2,18) 8.3, p 0.001) (Fig. 10D and Fig. 10-11, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f10-1). Recip-
rocally, suppressing the peripheral sources of noradrenaline pre-
vented the effect of chronic (but not acute) amitriptyline (chronic:
F(9,162) 6.8, p 0.001) (Fig. 10D and Fig. 10-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.2018.f10-1). We then evalu-
ated the role of adrenoceptors and observed that 2 adrenoceptors
(but not adrenoceptors) mediated acute amitriptyline action (yo-
himbine:F(1,16)6.3,p 0.005) (Fig. 10E and Fig. 10-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f10-1), whereas
the delayed action of chronic amitriptyline was lost in 2-AR
/
mice (F(8,120) 3.6, p 0.001) (Fig. 10F and Fig. 10-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f10-1). This an-
ti-allodynic action of chronic amitriptyline required DOR, but nei-
ther MOR nor KOR (DOR/: F(8,120) 3.4, p 0.001) (Fig. 10G
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and Fig. 10-1, available at https://doi.org/
10.1523/JNEUROSCI.1004-18.2018.f10-1),
with a likely peripheral location of the re-
quired opioid receptors, as shown by
naloxone methiodide action (F(3,39)  8.8,
p 0.001) (Fig. 10H and Fig. 10-1, available
at https://doi.org/10.1523/JNEURO-
SCI.1004-18.2018.f10-1). Furthermore, the
overexpression of mTNF- in the lumbar
dorsal root ganglia of nerve injured male
mice was also corrected by chronic amitrip-
tyline treatment (H(2,21)  6.4, p  0.041)
(Fig. 11 and Fig. 11-1, available at https://
doi.org/10.1523/JNEUROSCI.1004-18.
2018.f11-1). These data converge with du-
loxetine data, thus supporting the conclu-
sion that, for two types of antidepressant
medications, different mechanisms under-
lie their acute and delayed actions on neuro-
pathic pain.
Discussion
Although antidepressants have been used for several years as
first-line treatment against neuropathic pain, their mecha-
nism of action remains in part elusive (Kremer et al., 2016a).
The present study combined data collected in a preclinical model
of neuropathic pain and plasma dosage in the clinical setting to un-
derstand how antidepressant drugs act on neuropathic pain. We
provide evidence for two distinct adrenergic-mediated mechanisms
by which the SSNRI duloxetine and the tricyclic antidepressant am-
itriptyline relieved neuropathic allodynia. One of these mechanisms
is central, requiring descending noradrenergic inhibitory controls
and2A adrenoceptors, as well as the MOR and DOR components of
the opioid system. This central mechanism results in a rapid and
transitory relief of mechanical allodynia and it converges with vari-
ous reports from the animal-based scientific literature (Ardid and
Guilbaud, 1992; Marchand et al., 2003; Ozdog˘an et al., 2004; Suzuki
et al., 2008; Cegielska-Perun et al., 2013; Hajhashemi et al., 2014).
The other mechanism is peripheral, delayed but longer lasting (Sal-
vat et al., 2018), and requires noradrenaline from peripheral sympa-
thetic endings and2 adrenoceptors, as well as the DOR component
of the opioid system (Benbouzid et al., 2008b; Yalcin et al., 2009a,b;
Bohren et al., 2013; Choucair-Jaafar et al., 2014). This peripheral
mechanism provides a delayed relief of mechanical allodynia, con-
verges with reports from studies on chronic nortriptyline (Yalcin et
al., 2009b; Bohren et al., 2013), and relies on an anti-neuroimmune
action. Together, these findings suggest that the apparent mechanis-
tic discrepancies previously reported in the literature result from
differences in experimental procedures, which may more specifically
highlight one or the other (or both) of the above mechanisms de-
pending on the protocol chosen to deliver and test the action of the
antidepressant drugs.
To explore the clinical relevance of these mechanisms, we
compared drug levels in the animal model and in patients re-
lieved by at least 30% of their peripheral neuropathic pain by the
daily intake of a 60 mg dose of duloxetine. To circumvent inter-
species differences concerning intestinal absorption, metabo-
lism, or bioavailability of the drug, we directly performed plasma
dosage of duloxetine. Blood sampling in patients was done at
both peak levels (Senthamil Selvan et al., 2007) and residual levels
(before daily drug intake) and we compared the results with those
obtained in animals under acute and chronic treatments. We
showed that plasma concentrations in chronically treated neuro-
pathic pain patients are in agreement with reports from the liter-
ature that are based on acute delivery in naive volunteers
(Skinner et al., 2003; Reddy et al., 2012). We also observed that
these concentrations are in good agreement with the ones mea-
sured in animals under chronic treatment. Moreover, the human
versus mouse Ki values for duloxetine action on noradrenaline
uptake are in a close range (7.5 vs 3.6 nM) (Wong, 1998; Bymaster
et al., 2005), which excludes a main interspecies confounder
that would be related to differences in action on the noradren-
ergic transporter. Duloxetine concentrations observed in pa-
tients are in fact even slightly lower than the ones reached in
the animal model, which may be related to the fact that the
animal studies are based on a full recovery from mechanical
allodynia, whereas clinical criteria for efficacy are based on a
partial (30%) decrease in pain intensity.
4
(Figure legend continued.) 30 mg/kg. C, Chronic oral amitriptyline dose-dependently sup-
pressed cuff-induced allodynia at doses 100, 150, or 200g/ml. No effect was observed on the
contralateral paw or on the nociceptive threshold of sham mice. D, Guanethidine (peripheral
lesion, 30mg/kg, i.p.) and 6-OHDA (central lesion, 20g permouse, i.t.) allowed lesioning the
noradrenergic fibers. Acutely, a high dose of amitriptyline (15 mg/kg, i.p.) induced a rapid
anti-allodynic effect (left graph). This effect was prevented by a central (middle graph), but not
peripheral (right graph), noradrenergic lesion. Chronic amitriptyline (200 g/ml) exerted a
delayed anti-allodynic effect (left graph). The peripheral (right graph), but not central (middle
graph), noradrenergic lesion suppressed the long-term anti-allodynic action of amitriptyline.
(“Chronic No Lesion” n/”Acute No Lesion” n/”Chronic Peripheral Lesion” n/”Acute Peripheral
Lesion”n/”Chronic Central Lesion”n/”Acute Central Lesion”n are given in brackets).E, In nerve-
injured mice, yohimbine (2 adrenoceptor antagonist, 20g/ml for 5 d), but not propranolol
( adrenoceptor antagonist, 50g/ml for 5 d), suppressed the acute action of per os amitrip-
tyline (20 mg/kg). *p  0.05 compared with time before acute administration. F, In 2-
AR	/	 mice, chronic oral amitriptyline (200 g/ml) suppressed mechanical allodynia but
remained ineffective in2-AR/mice. “2-AR	/	 n/2-AR/ n” are given in brackets.
G, In WT mice, in MOR/ and in KOR/ mice, chronic oral amitriptyline treatment sup-
pressed the ipsilateral cuff-inducedallodynia,whereas it remained ineffective inDOR/mice
(“WT n/MOR/ n/DOR/ n/KOR/ n” are given in brackets).H, An acute injection of the
opioid receptor antagonist, naloxonemethiodide (5mg/kg, s.c.) induced a relapse of allodynia
in chronic amitriptyline-treated mice (“Saline n/NLX Meth n” are given in bracket). Ami, Ami-
triptyline; Sacch, saccharin. Data are expressed as mean SEM. “B” corresponds to the me-
chanical threshold sensitivity of right paw before surgery. AR, Adrenoceptor. n values are given
in brackets. *p 0.05 comparedwith sham saccharin groups. ANOVAwith repeatedmeasures
was used for A, C, D, and F–H; one-way ANOVA was used for B and E. Detailed statistics are
provided in Figure 10-1, available at https://doi.org/10.1523/JNEUROSCI.1004-18.
2018.f10-1.
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Figure 11. Impact of chronic amitriptyline treatment on TNF- levels in dorsal root ganglia. Neuropathic pain was induced by
inserting a cuff around themain branch of the sciatic nerve. Chronic oral amitriptyline treatment started at least 2 weeks postsur-
gery and lasted 3weeks. Thepresence and relief ofmechanical allodyniawere testedusing von Frey filaments. L4, L5, and L6dorsal
root ganglia were collected for molecular analysis. Western blot analysis of dorsal root ganglia showed increased TNF- levels in
male mice with nerve injury and an anti-TNF- action after chronic amitriptyline treatment (200g/ml). The histogram repre-
sents the relative amount of TNF- according to the density of the control group sham saccharin. Ami, Amitriptyline; Sacch,
saccharin. Data are expressed as mean SEM. n values are given in brackets. *p 0.05 compared with sham saccharin group;
#p 0.05 compared with cuff treatment group, Kruskal–Wallis test. Detailed statistics are provided in Figure 11-1, available at
https://doi.org/10.1523/JNEUROSCI.1004-18.2018.f11-1.
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To further investigate the peripheral mechanism of action of
duloxetine, we conducted a transcriptomic analysis in dorsal root
ganglia. This emphasized the extensive remodeling of the extra-
cellular matrix following nerve injury, as illustrated by changes in
metalloproteases, which converges with reports from other neu-
ropathic pain models or from other species (Komori et al., 2007;
Wu et al., 2016; Hirai et al., 2017). Metalloproteases from the
extracellular matrix, which are expressed by dorsal root ganglia
neurons and satellite cells, regulate the proliferation and differ-
entiation of peripheral (Chattopadhyay and Shubayev, 2009;
Berta et al., 2012) and central (Kawasaki et al., 2008) glial cells and
contribute to the development of neuropathic pain (Ji et al.,
2009). Therefore, a recruitment of glial and immunocompetent
cells is among the consequences of extracellular matrix alteration
(Kawasaki et al., 2008). In this context, our transcriptomic analysis
highlighted an anti-neuroimmune action of duloxetine. Neuroin-
flammation, which is often poorly sensitive to classical nonsteroidal
anti-inflammatory drugs (Colloca et al., 2017), is associated with
neuropathic pain pathophysiology (Ellis and Bennett, 2013; Lees et
al., 2015). Our data suggest that chronically administered antide-
pressant drugs may relieve neuropathic pain by targeting these
mechanisms. Interestingly, the anti-neuroimmune property of anti-
depressant drugs may not be limited to their action on neuropathic
pain. Indeed, major depression can also be associated with inflam-
mation (Dantzer et al., 2008; Walker et al., 2014; Miller and Raison,
2016; Pariante, 2017) and antidepressant drugs have been proposed
to affect immune/glial responses and cytokines (Ko¨hler et al., 2018;
Wie˛dłocha et al., 2018).
The TNF-–NF-B pathway is a key regulator of the produc-
tion of proinflammatory cytokines and of immune and glial re-
sponses (Makarov, 2000) and TNF- itself, which is located both
upstream and downstream of this pathway (Ledeboer et al., 2005;
Kaltschmidt and Kaltschmidt, 2009; Lee et al., 2009), has been
associated with the pathophysiology of neuropathic pain (Empl
et al., 2001; Uc¸eyler et al., 2007; Leung and Cahill, 2010; Wang et
al., 2016) and has even been proposed as a potential biomarker
for chronic neuropathic pain after spinal cord injury in patients
(Xu et al., 2015). In the dorsal root ganglia, we have previously
observed that mTNF- was produced by satellite glial cells
(Bohren et al., 2013), which might contribute to neuropathic
allodynia by influencing the nearby nociceptors through a local
cell– cell signaling communication. We show here that chronic
duloxetine, as well as chronic amitriptyline, suppressed the in-
crease in dorsal root ganglia mTNF- levels that accompanied
nerve injury. This action could have therapeutic relevance. In-
deed, the loss of mTNF- overexpression has also been observed
after prolonged treatments with other antidepressant drugs
(Bohren et al., 2013), as well as with a gabapentinoid (Kremer et
al., 2016b), the other first-line treatment for neuropathic pain.
Beyond this convergence in treatment action, we showed that
adalimumab and certolizumab, two anti-TNF- biotherapies, as
well as an NF-B inhibitor, were effective in alleviating neuro-
pathic allodynia in the animal model, which supports a key
pathophysiological role of this cytokine. A potential therapeutic
benefit of anti-TNF- biotherapies in neuropathic pain or in
chronic back or disc-related pain has been suggested both in
patients (Korhonen et al., 2004; Tobinick and Davoodifar, 2004;
Genevay et al., 2010, 2012; Ohtori et al., 2012) and in animal
models (Sommer et al., 2001; Zanella et al., 2008; Watanabe et al.,
2011; Bohren et al., 2013; Coelho et al., 2014). Interestingly,
whereas anti-TNF- biotherapies increase the risk of herpes zos-
ter (Strangfeld et al., 2009; Failla et al., 2012; Di Costanzo et al.,
2013; Nimmrich and Horneff, 2015), the incidence of posther-
petic neuralgia might be lower (Javed et al., 2011). However,
whereas our data provide mechanistic evidence for the anti-
neuroimmune action of antidepressant drugs, direct anti-TNF-
treatments may not be appropriate for a large clinical use in a
neuropathic pain context. Indeed, the benefits/risks balance can
be questioned due to major adverse effects, including increased
risks of infections and of cancer (Pereira et al., 2015; Cosnes,
2017). In this context, it may be of interest to develop new ther-
apies that would blunt pathological TNF- overexpression, but
partly maintain its physiological production.
Our results also highlighted the contribution of other mem-
bers of the TNF-–NF-B signaling pathway, including TLR2.
TLRs are type I transmembrane receptors expressed in innate
immune cells that detect pathogen-associated molecules and
trigger inflammatory responses (Hayward and Lee, 2014). Due to
their ability to also recognize damage-associated molecular pat-
tern molecules (DAMPs), TLRs can be involved in glial activation
and contribute to noninfectious disorders, including persistent
pain (Hayward and Lee, 2014; Kato and Svensson, 2015). Indeed,
it has been suggested that TLR2 is responsible for the nerve
injury-induced satellite glial cell activation and TNF- upregula-
tion in the dorsal root ganglia and thereby contributes to the
development of neuropathic pain (Kim et al., 2007, 2011). A
repeated intrathecal delivery of a nonselective TLR2/4 antagonist
can attenuate allodynia in a neuropathic pain model (Jurga et al.,
2016). Here, we show that allodynia relief can also be observed
after the systemic delivery of such antagonist, as well as with a
selective anti-TLR2 biotherapy. Interestingly, anti-TLR2 drugs
are presently under investigation for human application in my-
elodysplastic syndrome and in preventing delayed renal graft
function. We show here that duloxetine, through a 2 adreno-
ceptor-mediated mechanism, indirectly acts as an anti-TLR2 by
regulating its overexpression in a pathological context.
In conclusion, we identified two independent mechanisms
contributing to the action of antidepressant drugs on neuro-
pathic pain. In particular, our transcriptomic analysis suggests
that the peripheral component of duloxetine action involves the
inhibition of neuroimmune mechanisms accompanying nerve
injury, including the downregulation of the TNF-–NF-B sig-
naling pathway. These findings reveal antidepressant drugs as
indirectly affecting neuroinflammatory mechanisms, which, be-
yond the pain field, might also be relevant to the psychiatric
applications of these molecules.
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